> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Abbvie sNDA for Viekira Pak Approved
- URL: https://www.fdaweb.com/abbvie-snda-for-viekira-pak-approved/
- Published: 2016-04-25T12:00:00.000Z
- Updated: 2026-09-14T20:57:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135480

> FDA has approved an AbbVie supplemental NDA for Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without ribavirin (RBV) in patients with genotype 1b (GT1b) chronic hepatitis C virus and compensated cirrhosis (Child-Pugh A). The current dosing recommendation for patients with GT1b and compensated cirrhosis is to administer RBV with Viekira Pak for 12 weeks.  
>  
> The submission was supported with data from the company’s TURQUOISE-III study that evaluated the use of Viekira Pak without RBV for 12 weeks in GT1b patients with compensated cirrhosis (Child-Pugh A). “Results demonstrated 100% (N=60/60) sustained virologic response at 12 weeks post-treatment,” the company says. No patients discontinued treatment due to adverse events, it says.